Get the Stockscreener App
10.69
2.88%
0.28
After Hours:
10.69
Rocket Pharmaceuticals Inc stock is traded at $10.69, with a volume of 2.10M.
It is up +2.88% in the last 24 hours and down -10.97% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
See More
Previous Close:
$10.41
Open:
$10.51
24h Volume:
2.10M
Relative Volume:
1.62
Market Cap:
$1.14B
Revenue:
-
Net Income/Loss:
$-249.31M
P/E Ratio:
-3.7247
EPS:
-2.87
Net Cash Flow:
$-209.70M
1W Performance:
-3.34%
1M Performance:
-10.97%
6M Performance:
-56.39%
1Y Performance:
-63.02%
1-Day Range:
$10.25
$10.79
1-Week Range:
$10.20
$11.31
52-Week Range:
$10.07
$31.47
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
10.69 | 1.14B | 0 | -249.31M | -209.70M | -2.87 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | Wedbush | Outperform |
| Dec-18-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-23 | Initiated | Morgan Stanley | Overweight |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Nov-01-22 | Initiated | BTIG Research | Buy |
| Jul-08-22 | Initiated | Raymond James | Outperform |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Feb-18-21 | Initiated | Needham | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-02-20 | Initiated | JP Morgan | Overweight |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-26-19 | Initiated | Piper Jaffray | Overweight |
| Apr-23-19 | Initiated | Robert W. Baird | Outperform |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Feb-05-19 | Initiated | Oppenheimer | Outperform |
| Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
| Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
Rocket Pharmaceuticals appoints new board member By Investing.com - Investing.com Nigeria
Rocket Pharmaceuticals appoints new board member - Investing.com
Rocket Pharmaceuticals, Inc. Announces Board Changes -January 28, 2025 at 06:03 am EST - Marketscreener.com
Rocket Pharmaceuticals vice president sells $9,300 in stock - MSN
(RCKT) Technical Pivots with Risk Controls - Stock Traders Daily
Rocket Pharmaceuticals vice president sells $9,300 in stock By Investing.com - Investing.com Canada
Leerink Partnrs Has Strong Forecast for RCKT FY2024 Earnings - Defense World
FY2024 Earnings Estimate for RCKT Issued By Leerink Partnrs - MarketBeat
Analysts Offer Predictions for RCKT FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts RCKT FY2025 Earnings - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 52-Week LowHere's What Happened - MarketBeat
Analysts Set Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Price Target at $47.27 - MarketBeat
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Rating of “Moderate Buy” by Analysts - Defense World
RCKT stock touches 52-week low at $10.11 amid market challenges - MSN
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 12-Month Low – Time to Sell? - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Down 4%Here's Why - MarketBeat
How to Take Advantage of moves in (RCKT) - Stock Traders Daily
Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Acquired by Mirador Capital Partners LP - MarketBeat
JPMorgan Chase & Co. Decreases Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Hits New 12-Month LowHere's What Happened - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Up 6.9%Time to Buy? - MarketBeat
Learn to Evaluate (RCKT) using the Charts - Stock Traders Daily
RCKTRocket Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Q4 Earnings Estimate for RCKT Issued By Wedbush - Defense World
Brokers Set Expectations for RCKT Q4 Earnings - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Trading 3.7% HigherWhat's Next? - MarketBeat
Wedbush starts Rocket Pharmaceuticals with Outperform into ‘inflection year’ - Yahoo Finance
Rocket Pharmaceuticals (NASDAQ:RCKT) Now Covered by Analysts at Wedbush - Defense World
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock poised for growth - Investing.com Canada
Rocket Pharmaceuticals (NASDAQ:RCKT) Now Covered by Wedbush - MarketBeat
Rocket Pharmaceuticals, Inc. (RCKT): Is This Gene Therapy Stock a Good Buy Right Now? - Yahoo Finance
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey
(RCKT) On The My Stocks Page - Stock Traders Daily
Geode Capital Management LLC Boosts Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Position Decreased by HighTower Advisors LLC - Defense World
Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy' - MSN
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 1-Year LowHere's Why - MarketBeat
State Street Corp Buys 322,156 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Franklin Resources Inc. Cuts Stock Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
State Street Corp Has $57.29 Million Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Gap UpShould You Buy? - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Now Covered by Jefferies Financial Group - MarketBeat
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.46%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):